New drug targets Hard-to-Treat cancers with MET gene change

NCT ID NCT07196644

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will monitor side effects and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: telisotuzumab adizutecan
What this could lead to: If successful, this could provide a new treatment option for people with advanced cancers that have a specific genetic change (MET amplification).
What could go wrong: This is an early-phase trial with only 100 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS HARBORING MET AMPLIFICATION

Contacts and locations

Locations

Beverly Hills Cancer Center /ID# 275465
RECRUITING

Beverly Hills, California, 90211, United States
City of Hope National Medical Center /ID# 275613
RECRUITING

Duarte, California, 91010, United States
Clinica Universidad de Navarra - Pamplona /ID# 275503
RECRUITING

Pamplona, Navarre, 31008, Spain
Dell Seton Medical Center /ID# 276474
RECRUITING

Austin, Texas, 78701, United States
Duke Cancer Institute /ID# 275604
RECRUITING

Durham, North Carolina, 27710, United States
Florida Cancer Specialists - North /ID# 277137
RECRUITING

St. Petersburg, Florida, 33705, United States
Hadassah Medical Center-Hebrew University /ID# 274343
RECRUITING

Jerusalem, 91120, Israel
Hokkaido University Hospital /ID# 276333
RECRUITING

Sapporo, Hokkaido, 060-8648, Japan
Hospital Clinico Universitario de Valencia /ID# 275501
RECRUITING

Valencia, 46010, Spain
Hospital General Universitario Gregorio Maranon /ID# 275498
RECRUITING

Madrid, 28007, Spain
Hospital Universitario 12 de Octubre /ID# 275496
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Vall de Hebron /ID# 275499
RECRUITING

Barcelona, 08035, Spain
Kyoto University Hospital /ID# 276398
RECRUITING

Kyoto, Kyoto, 606-8507, Japan
Kyushu University Hospital /ID# 276302
RECRUITING

Fukuoka, Fukuoka, 812-8582, Japan
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999
RECRUITING

New York, New York, 10065, United States
Nagoya University Hospital /ID# 276336
RECRUITING

Nagoya, Aichi-ken, 466-8560, Japan
National Cancer Center Hospital /ID# 276297
RECRUITING

Chuo-Ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East /ID# 276298
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
Northwestern University Feinberg School of Medicine /ID# 276436
RECRUITING

Chicago, Illinois, 60611-2927, United States
Okayama University Hospital /ID# 276299
RECRUITING

Okayama, Okayama-ken, 700-8558, Japan
Rabin Medical Center. /ID# 274341
RECRUITING

Petah Tikva, Central District, 4941492, Israel
SCRI Oncology Partners /ID# 275686
RECRUITING

Nashville, Tennessee, 37203, United States
START Midwest /ID# 276603
RECRUITING

Grand Rapids, Michigan, 49546, United States
Samsung Medical Center /ID# 275705
RECRUITING

Seoul, Seoul Teugbyeolsi, 06351, South Korea
Seoul National University Hospital /ID# 275703
RECRUITING

Seoul, Seoul Teugbyeolsi, 03080, South Korea
South Texas Accelerated Research Therapeutics /ID# 276608
RECRUITING

San Antonio, Texas, 78229, United States
Stanford University - Palo Alto /ID# 282083
RECRUITING

Palo Alto, California, 94304, United States
Start Mountain Region /ID# 276607
RECRUITING

West Valley City, Utah, 84119, United States
Tel Aviv Sourasky Medical Center /ID# 274344
RECRUITING

Tel Aviv, Tel Aviv, 6423906, Israel
The Chaim Sheba Medical Center /ID# 274342
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel
The University of Texas MD Anderson Cancer Center /ID# 275663
RECRUITING

Houston, Texas, 77030, United States
Tohoku University Hospital /ID# 276344
RECRUITING

Sendai, Miyagi, 980-8574, Japan
University of Chicago Medical Center /ID# 275342
RECRUITING

Chicago, Illinois, 60637, United States
University of Texas - Southwestern Medical Center /ID# 276053
RECRUITING

Dallas, Texas, 75235, United States
Valkyrie Clinical Trials /ID# 275547
RECRUITING

Los Angeles, California, 90067, United States
Virginia Cancer Specialists - Fairfax /ID# 276010
RECRUITING

Fairfax, Virginia, 22031, United States
Yale University School of Medicine /ID# 275978
RECRUITING

New Haven, Connecticut, 06510, United States
Yonsei University Health System Severance Hospital /ID# 276184
RECRUITING

Seoul, Seoul Teugbyeolsi, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.